The overall effectiveness of nicotine replacement therapy could be greater if the therapy were targeted at those most likely to respond. Variants of the dopamine D2 receptor (DRD2 32806 C/T) have been implicated in the initiation and maintenance of smoking, 1 2 and these variants may also be related to response to nicotine replacement therapy.
Participants, methods, and results
A randomised controlled trial of nicotine patches in 1991-2 recruited 1686 heavy smokers ( ≥ 15 cigarettes a day). 5 The participants wore patches for 12 weeks. Abstinence from smoking was confirmed at one week by expired carbon monoxide concentration ≤ 10 ppm, and at 12, 24, and 52 weeks by salivary cotinine concentration ≤ 20 ng/ml (89% of cases) or by expired carbon monoxide concentration ≤ 10 ppm.
In 1999-2000, we contacted 1532 of the 1625 participants still alive; the mean time from trial to follow up was 8.3 years. In all, 752/1532 (49%) gave a blood sample from which DRD2 32806 was successfully typed. Reported abstinence at follow up was confirmed by plasma cotinine concentration ≤ 20 ng/ml. Throughout, non-respondents were assumed to be smoking.
Participants were older than non-participants (mean age at entry to trial, 43.0 years v 41.5 years; P = 0.002), more likely to be female (59% (445/752) v 53% (410/780); P = 0.01), and more likely to have quit for a year in the trial (11% (82) v 4% (33), P < 0.0001); 744 (99%) reported their racial background as white.
The variant T allele of the dopamine D2 receptor DRD2 32806 (CT or TT genotype) was found in 41% (183/445) of women and 41% of men (127/307). Within each sex, there was no difference between the genotype groups in age, number of cigarettes a day, or dependency score.
We measured effectiveness of the patches by the relative odds of abstinence for active and placebo patches over five cumulative time periods: one week, 12 weeks, 24 weeks, 52 weeks, and to follow up. Treatment by genotype and sex, and their interaction, was examined in a full logistic regression model. The three way interaction by genotype by sex was significant for all time periods (P = 0.009, P = 0.03, P = 0.006, P = 0.006, P = 0.004 respectively), and we therefore analysed the data for men and women separately.
In women, the effectiveness of the patches differed with genotype at all time points (table). In men the genotype groups did not differ significantly at any time. In men with CC genotype an apparent trend in effectiveness was in an implausible direction, the patches being most effective long after therapy had stopped. In both sexes, when active and placebo groups were combined, the quit rate was not related to genotype.
Comment
In women the effectiveness of nicotine patches seems to be related to genotype. Women with the variant T allele of the dopamine D2 receptor DRD2 32806 showed considerable benefit from patches, whereas those with the more common CC genotype did not. The increased effectiveness reflected a tendency to a higher quit rate with the active patches and a lower quit rate with placebo patches. No significant relation between genotype and patch effectiveness was seen for men.
Modelling showed that the response bias in favour of quitters and of women could not account for our results, as the bias affected the nicotine and placebo groups equally and so cancels out in the odds ratio for patch effectiveness. The results are also not explained by an association between genotype and success at quitting, as this could account for only a marginal difference in odds ratios between genotypes and would affect men and women similarly. We therefore hypothesise that nicotine replacement therapy works through different processes and is subject to different genetic influences in men and women.
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